CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma
RATIONALE: CT-322 may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.

PURPOSE: This phase I trial is studying the side effects of CT-322 in treating patients with advanced solid tumors or non-Hodgkin's lymphoma.
Cancer
DRUG: CT-322
Safety and tolerability of CT-322, Throughout the study
To evaluate the pharmacokinetics of CT-322 in these patients;, Throughout the study|to assess whether antibodies to this drug develop in these patients; and, Throughout the study|to make a preliminary assessment of the biological activity of CT-322 to alter tumor growth., Throughout the study
RATIONALE: CT-322 may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.

PURPOSE: This phase I trial is studying the side effects of CT-322 in treating patients with advanced solid tumors or non-Hodgkin's lymphoma.